Search results
Added:
7 months ago
Learn about revascularisation strategies in cardiogenic shock after acute MI, including culprit-only vs multivessel PCI, from Dr Tara Jones (University of Utah, US).This three-part video lecture series, part of Women As One’s CLIMB® 2025 Skills Training Programme, offers case-based insights into Coronary and Mechanical Support for Cardiogenic Shock, curated by Dr Alison Duncan and Dr Frederick…
View more
Added:
7 months ago
Learn about the definition and implications of a shock diagnosis and systems of care and the role of the shock team from Dr Frederick Welt (University of Utah, US).This three-part video lecture series, part of Women As One’s CLIMB® 2025 Skills Training Programme, offers case-based insights into Coronary and Mechanical Support for Cardiogenic Shock, curated by Dr Alison Duncan and Dr Frederick…
View more
Added:
1 year ago
ESC 2024 - We are joined by Dr Michelle Kittleson (Cedars-Sinai Heart Institute, US) for a concise and insightful summary of the hot-line and late-breaking data that is expected to have an impact on heart failure care.Trials covered in detail include:FINEARTS HFHELIOS-BRESHAPE HF2Recorded remotely from Los Angeles, 2024.Editors: Jordan Rance and Mirjam Boros.Videographers: Mike Knight, Dan Brent,…
View more
ESC HF 25: SCD-PROTECT
Added:
1 year ago
Video
Added:
7 months ago
HFSA 25 - Aficamten found to significantly improve NYHA and KCCQ-CSS scores in new 96-week data from FOREST-HCM.Dr Ahmad Masri (Oregon Health & Science University, US) joins us to discuss findings from the FOREST-HCM trial, examining the sustained safety and efficacy of aficamten in patients with symptomatic nonobstructive hypertrophic cardiomyopathy.This phase 2 open-label study followed 34…
View more
Added:
5 months ago
Navigate the diagnostic and therapeutic landscape of autoimmune disorders and cardiomyopathy with Dr Heba WassifThis presentation, part of the comprehensive Cardiomyopathies track, explores the critical intersection between immune-mediated inflammatory disorders and cardiovascular disease.Dr Wassif examines the spectrum and epidemiology of immune-mediated inflammatory disorders, emphasizing their…
View more
Added:
1 year ago
ESC Congress 24 – Day 1 of the ESC Congress 2024 was filled with excitement as new clinical practice guidelines were unveiled, along with several highly anticipated Hot Line trials.Interventional experts Dr Mirvat Alasnag and Dr Khaled Al-Shaibi (King Fahd Armed Forces Hospital, SA) are concluding the first day by providing practical summaries of the key guidelines and offering critical insights…
View more
Added:
1 year ago
AHA Conference 2024 - 22 month data from the risk evaluation and mitigation strategy (REMS) program for mavacamten (Camzyos; Bristol-Myers Squibb Company) in hypertrophic cardiomyopathy (HCM) patients.Dr Milind Desai (Cleveland Clinic, Ohio, US) joins us onsite at AHA Conference to discuss the findings from the REMS program for mavacamten.The REMS program investigated the safety and efficacy of…
View more
Added:
1 year ago
In this Meet the Experts session, from e-SPACE Heart Failure 2024, Prof Marianna Fontana and Prof Arnt Kristen explore the management of transthyretin amyloid cardiomyopathy (ATTRCM) and discuss strategies for optimising patient care pathways.
View more
Added:
1 year ago
AHA Conference 2024 - Safety and efficacy outcomes of nexiguran ziclumeran (NTLA-2001) in patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM).Dr Marianna Fontana (University College London, London, UK) joins us onsite at AHA Conference to discuss the findings from the nexiguran ziclumeran for ATTR-CM trial (NCT04601051).Dr Fontana discusses a phase 1, ongoing, open-label, single…
View more